ESR1 and breast carcinoma: Nonetheless, the same group later confirmed that LEPR2A also reduces tumor growth rate and VEGF/VEGFR2 levels in ER+ (MCF7) and ER- (MDA-MB-231) breast cancer cells and tumor xenografts (154).